MALMÖ, SE / ACCESS Newswire / February 5, 2026 / Ascelia Pharma AB (publ) (ticker:ACE)(STO:ACE) today published its Full Year and Q4 Report for 2025 (January - December), which is now available on the ...
The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...
A new drug application (NDA) has been submitted to the FDA seeking approval of lirafugratinib (RLY-4008), a selective FGFR2 ...
The FDA approved re-administration of iDose TR for patients with healthy corneas, enhancing treatment flexibility for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results